The combination of splenic UTMC with systemic aPD-L1 inhibited tumor growth and enhanced the frequency of splenic IFN-γ+ CTLs and IFN-γ+ CD4+ cells while reducing TGF-β+ CD11b+ cells [181]. This evidence concerns the gene IFNG and neoplasm.